SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Trinity Biotech (TRIBY)
TRIB 0.696-1.1%Jan 14 3:51 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Peter Caradonna who wrote (2949)11/12/1996 11:23:00 AM
From: b muller   of 14328
 
Peter here's some news on avit I thought you might want to see!!

Avitar, Inc. signs agreement with Sun Biomedical Laboratories

WALLINGFORD, Conn.--(BUSINESS WIRE)--Nov. 12, 1996--Avitar, Inc. (Nasdaq SmallCap
Market:AVIT (Common
Stock); AVITW (Redeemable Warrants)) today announced that it has signed an agreement with Sun
Biomedical Laboratories
of Cherry Hill, New Jersey, to develop a series of saliva- based, rapid screening tests for drugs of abuse. Sun
Biomedical
Laboratories currently has FDA approval to market six urine-based, rapid screening tests for drugs of abuse as
well as a
pregnancy test, all marketed under the Visuline II trademark.

The saliva test will use Avitar's proprietary saliva collection system, with Avitar having the exclusive,
world-wide
manufacturing and distribution rights to the tests when the development is completed. In addition to the
development
agreement, Avitar will begin manufacturing the currently-marketed urine-based tests and will have
non-exclusive distribution
rights to these tests.

Avitar also announced that Dr. Ming Sun, President of Sun Biomedical Laboratories, will join Avitar's
Scientific Advisory
Board.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext